Avalyn Pharma Inc. (AVLN) income statement
AVLNNasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 12, 2026
$27.69−0.23 (-0.82%)
Close on Nov 18, 2026Market cap $1.23BP/E –Yield –
Avalyn Pharma Inc. income statement
Ratios
Latest available, balances at Jun 30, 2026
Profitability, FY
- Gross margin
- –
- Operating margin
- –
- Net margin
- –
- Return on equity, FY2025
- –
Financial strength
- Current ratio
- 33.12
- Debt to equity
- 0.04
- Debt to assets
- 3.5%
- Cash to current liabilities
- 2444.2%
Valuation
- P/E ratio
- –
- Price to sales
- –
- Price to book
- 3.08
- Dividend yield
- –
See a number that looks wrong?